- Home
- SCLXW vs GGZ Comparison
SCLXW vs GGZ Comparison
Compare SCLXW & GGZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLXW
- GGZ
- Stock Information
- Founded
- SCLXW N/A
- GGZ 2013
- Country
- SCLXW United States
- GGZ United States
- Employees
- SCLXW N/A
- GGZ N/A
- Industry
- SCLXW Biotechnology: Pharmaceutical Preparations
- GGZ Investment Managers
- Sector
- SCLXW Health Care
- GGZ Finance
- Exchange
- SCLXW Nasdaq
- GGZ Nasdaq
- Market Cap
- SCLXW N/A
- GGZ N/A
- IPO Year
- SCLXW N/A
- GGZ N/A
- Fundamental
- Price
- SCLXW $0.11
- GGZ $12.38
- Analyst Decision
- SCLXW
- GGZ
- Analyst Count
- SCLXW 0
- GGZ 0
- Target Price
- SCLXW N/A
- GGZ N/A
- AVG Volume (30 Days)
- SCLXW 4.0K
- GGZ 12.8K
- Earning Date
- SCLXW 03-07-2025
- GGZ 01-01-0001
- Dividend Yield
- SCLXW N/A
- GGZ 5.39%
- EPS Growth
- SCLXW N/A
- GGZ N/A
- EPS
- SCLXW N/A
- GGZ 1.75
- Revenue
- SCLXW $55,152,000.00
- GGZ N/A
- Revenue This Year
- SCLXW N/A
- GGZ N/A
- Revenue Next Year
- SCLXW N/A
- GGZ N/A
- P/E Ratio
- SCLXW N/A
- GGZ $6.79
- Revenue Growth
- SCLXW 22.02
- GGZ N/A
- 52 Week Low
- SCLXW $0.18
- GGZ $9.43
- 52 Week High
- SCLXW $0.18
- GGZ $12.50
- Technical
- Relative Strength Index (RSI)
- SCLXW N/A
- GGZ 50.68
- Support Level
- SCLXW N/A
- GGZ $12.50
- Resistance Level
- SCLXW N/A
- GGZ $12.68
- Average True Range (ATR)
- SCLXW 0.00
- GGZ 0.15
- MACD
- SCLXW 0.00
- GGZ 0.01
- Stochastic Oscillator
- SCLXW 0.00
- GGZ 45.59
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.